Page 66 - 84_04
P. 66
AGRADECIMIENTOS of thiopurines. Cancer Chemother Rep 1962; 16: 197-
El autor agradece a Marina Mojena y Adrián Povo- 202.
Retana por la revisión crítica del texto. La financiación de 6. Beutler E, McMillan R. Bone marrow transplantation
la Comunidad de Madrid (S2017/BMD-3686), Fundación in acute leukemia. Blood Cells 1982; 8: 485-500.
Ramón Areces (CIVP18A3864) y RTC-2017-6283 y
Fondos FEDER. 7. Nass SJ, Rothenberg ML, Pentz R, et al. Accelerating
anticancer drug development - opportunities and
REFERENCIAS DESTACADAS trade-offs. Nat Rev Clin Oncol 2018; 15: 777-86.
Ishida Y, Agata Y, Shibahara K, Honjo T. Induced 10.1038/s41571-018-0102-3
expression of PD-1, a novel member of the 8. Ngwa W, Irabor OC, Schoenfeld JD, Hesser J,
immunoglobulin gene superfamily, upon programmed Demaria S, Formenti SC. Using immunotherapy to
cell death. EMBO J 1992; 11(11): 3887-95. boost the abscopal effect. Nat Rev Cancer 2018; 18:
Leach DR, Krummel MF, Allison JP. Enhancement of 313-22. 10.1038/nrc.2018.6
antitumor immunity by CTLA-4 blockade. Science
1996; 271: 1734-36. 9. Stanczak MA, Siddiqui SS, Trefny MP, et al. Self-
Kwon ED, Hurwitz AA, Foster BA, et al. Manipulation of associated molecular patterns mediate cancer immune
T cell costimulatory and inhibitory signals for evasion by engaging Siglecs on T cells. J Clin Invest
immunotherapy of prostate cancer. Proc Natl Acad Sci 2018; 128: 4912-23. 10.1172/jci120612
USA 1997; 94: 8099-103.
Nishimura H, Nose M, Hiai H, Minato N, Honjo T. 10. Okazaki T, Honjo T. The PD-1-PD-L pathway in
Development of Lupus-like Autoimmune Diseases by immunological tolerance. Trends Immunol 2006; 27:
Disruption of the PD-1 gene encoding an ITIM motif- 195-201. 10.1016/j.it.2006.02.001
carrying immunoreceptor. Immunity 1999; 11_ 141-
51. 11. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from
Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the discovery to clinical application. Int Immunol 2007;
PD-1 immunoinhibitory receptor by a novel B7 family 19: 813-24. 10.1093/intimm/dxm057
member leads to negative regulation of lymphocyte
activation. J Exp Med 2000; 192: 1027-34. 12. Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a
Hodi FS, Mihm MC, Soiffer RJ, et al.. Biologic activity of second ligand for PD-1 and inhibits T cell activation.
cytotoxic T lymphocyte-associated antigen 4 antibody Nat Immunol 2001; 2: 261-8. 10.1038/85330
blockade in previously vaccinated metastatic
melanoma and ovarian carcinoma patients. Proc Natl 13. Blank C, Brown I, Peterson AC, et al. PD-L1/B7H-1
Acad Sci USA 2003; 100: 4712-17. inhibits the effector phase of tumor rejection by T cell
Iwai Y, Terawaki S, Honjo T. PD-1 blockade inhibits receptor (TCR) transgenic CD8+ T cells. Cancer Res
hematogenous spread of poorly immunogenic tumor 2004; 64: 1140-5.
cells by enhanced recruitment of effector T cells. Int
Immunol 2005; 17: 133-44. 14. Iwai Y, Terawaki S, Honjo, T. PD-1 blockade inhibits
hematogenous spread of poorly immunogenic tumor
REFERENCIAS cells by enhanced recruitment of effector T cells. Int
1. Chamoto K, Al-Habsi M, Honjo T. Role of PD-1 in Immunol 2005; 17: 133-44. 10.1093/intimm/dxh194
Immunity and Diseases. Curr Top Microbiol Immunol 15. Chamoto K, Chowdhury PS, Kumar A, et al.
2017; 410: 75-97. 10.1007/82_2017_67 Mitochondrial activation chemicals synergize with
2. Kaiser J, Couzin-Frankel J. Cancer immunotherapy surface receptor PD-1 blockade for T cell-dependent
sweeps Nobel for medicine. Science 2018; 362: 13. antitumor activity. Proc Natl Acad Sci USA 2017;
10.1126/science.362.6410.13 114: E761-e770. 10.1073/pnas.1620433114
3. Yoshida T, Jiang F, Honjo T, Okazaki, T. PD-1
deficiency reveals various tissue-specific 16. Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T.
autoimmunity by H-2b and dose-dependent A rheostat for immune responses: the unique
requirement of H-2g7 for diabetes in NOD mice. Proc properties of PD-1 and their advantages for clinical
Natl Acad Sci USA 2008; 105: 3533-8. application. Nat Immunol 2013; 14: 1212-8.
10.1073/pnas.0710951105 10.1038/ni.2762
4. Mouraviev V, Gleave ME. A meaningful legacy:
urologists as Nobel Prize laureates. Can J Urol 2003; 17. Nishimura H, Nose M, Hiai H, Minato N, Honjo T.
10: 1737-42. Development of lupus-like autoimmune diseases by
5. Elion EB, Callahan SW, Hitchings GH, Rundles RW, disruption of the PD-1 gene encoding an ITIM motif-
Laszlo J. Experimental, clinical, and metabolic studies carrying immunoreceptor. Immunity 1999; 11: 141-
51.
@Real Academia Nacional de Farmacia. Spain
18. Formenti SC, Rudqvist NP, Golden E, et al.
Radiotherapy induces responses of lung cancer to
CTLA-4 blockade. Nat Med 2018; 24: 1845-51.
10.1038/s41591-018-0232-2
19. Goh KI, Cusick ME, Valle D, Childs B, Vidal M,
Barabasi AL. The human disease network. Proc Natl
Acad Sci USA 2007; 104: 8685-90.
10.1073/pnas.0701361104
393
